Keymed Biosciences Inc. (HKG:2162)
Hong Kong · Delayed Price · Currency is HKD 79.35
-1.35 (-1.67%)
Apr 17, 2026, 2:45 PM HKT
Keymed Biosciences Market Cap
Keymed Biosciences has a market cap or net worth of 23.77 billion as of April 16, 2026. Its market cap has increased by 125.82% in one year.
Market Cap
23.77B
Enterprise Value
22.51B
Revenue
797.12M
Ranking
n/a
PE Ratio
n/a
Stock Price
79.35
Market Cap Chart
Since July 8, 2021, Keymed Biosciences's market cap has increased from 18.43B to 23.77B, an increase of 29.01%. That is a compound annual growth rate of 5.48%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Apr 16, 2026 | 23.77B | 50.98% |
| Dec 31, 2025 | 15.75B | 84.90% |
| Dec 31, 2024 | 8.52B | -37.32% |
| Dec 29, 2023 | 13.59B | -4.15% |
| Dec 30, 2022 | 14.17B | 46.87% |
| Dec 31, 2021 | 9.65B | -47.63% |
| Jul 8, 2021 | 18.43B | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| InnoCare Pharma | 30.13B |
| Shanghai Bao Pharmaceuticals | 29.29B |
| Genscript Biotech | 27.79B |
| TransThera Sciences (Nanjing) | 27.75B |
| Duality Biotherapeutics | 25.85B |
| Ascentage Pharma Group International | 19.54B |
| Zai Lab | 19.38B |
| Nanjing Leads Biolabs | 18.48B |